

DAFTAR PUSTAKA

1. World Health Organization. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization. 2020; 14-24.
2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, *et al.* Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study. *Lancet.* 2020; 395–11.
3. Al-Sunaidar KA, Aziz NA, Hassan Y, Jamshed S, Sekar M. Association of multidrug resistance bacteria and clinical outcomes of adult patients with sepsis in the intensive care unit. *Trop Med Infect Dis.* 2022; 365(7): 1–15
4. Chun K, Syndergaard C, Damas C, Trubey R, Mukindaraj A, Qian S *et al.* Sepsis pathogen identification. *J Lab Automation.* 2015; 20(5): 539–61
5. Umemura Y, Ogura H, Takuma K, Fujishima S, Abe T, Kushimoto S *et al.* Current spectrum of causative pathogens in sepsis: a prospective nationwide cohort study in japan. *Int J Infect Dis.* 2021; 103: 343–51
6. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing enterobacteriaceae in europe. *Euro Surveill.* 2008; 13(47): 1-11
7. Toyyibah ID, Rusli M, Juniastuti. Bacterial pattern among sepsis patient in internal ward dr.soetomo general academic hospital surabaya. *Biomorphology Journal.* 2022; 2(32): 52-58
8. Paterson DL, Bonomo RA. Extended spectrum beta lactamases: a clinical update. *Clin Microbiol Rev.* 2005; 18(4): 657–86
9. Fadrian, Linosefa. *Buku saku antibiogram rsup dr. m. djamil padang tahun 2022.* komite pengendalian resistensi antibiotik tahun 2022. 2022
10. Kuntaman, Karuniawati A, Anggaraini D, Santosaningsih D, Septawati L. Cahyarini dkk. *Surveilans resistansi antibiotik rumah sakit di indonesia tahun 2021.* Perhimpunan Dokter Spesialis Mikrobiologi Indonesia. Jakarta. 2022; 82-86

11. Peirovifar A, Rezaee M, Gharehbaghi MM. Prevalence of multidrug resistant extended-spectrum beta-lactamase producing gram negative bacteria in neonatal sepsis. *Int J Women's Health and Reproduction Sci.* 2014; 2(4): 138–45
12. Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, *et al.* Infections caused by extended-spectrum beta-lactamases producing enterobacteriaceae: clinical and economic impact in patients hospitalized in 2 teaching hospitals in dakar, senegal. *Antimicrob Resist Infect Control.* 2016; 5: 13-18
13. Lee CH, Chu FY, Hsieh CC, Hong MY, Chi CH, Ko WC *et al.* A simple scoring algorithm predicting extended-spectrum β -lactamase producers in adults with community-onset monomicrobial enterobacteriaceae bacteremia: matters of frequent emergency department users. *Medicine Baltimore.* 2017; 4; 96(16): e6648.
14. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DSM, Urassa WK *et al.* High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in dar es salaam, tanzania. *J Clin Microbiol.* 2005; 43: 745–9
15. Rhodes A, Evans L, Alhazzani W, Levy MM, Antonell M, Ferrer R *et al.* Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med:* 2017; 43(3): 488-552
16. Luo Y, Guo Z, Ouyang H, Huang S, Chen Y, Li K *at al.* Appropriateness of empirical antibiotik therapy in bacterial culture- positive inpatients: a retrospective cohort study. *Research Square.* 2023; 16(3): 4555–568
17. Madrid-Morales J, Sharma A, Reveles,K, Velez-Mejia C, Hopkins T, Yang L *et al.* Validation of available extended spectrum beta lactamase clinical scoring models in predicting drug resistance in patients with enteric gram-negative bacteremia treated at south Texas veteran health care system. *Antimicrob Agents Chemother.* 2021; 65(6): 1-5
18. Tumbarello M, Treçarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, *et al.* Identifying patients harboring extended-spectrum-beta- lactamase-producing enterobacteriaceae on hospital admission: derivation

- and validation of a scoring system. *Antimicrob Agents Chemother* 2011; 55: 3485–490.
19. Mardia AI, Kembaren T. Penilaian akurasi italian score sebagai prediktor infeksi extended-spectrum β -lactamase (ESBL). *USU repository*: 2015: 1-77
 20. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, *et al.* The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA*. 2016; 315(8): 801–10.
 21. Menteri Kesehatan Republik Indonesia. Pedoman nasional pelayanan kedokteran tata laksana sepsis. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017: 5-6
 22. Hidayati, Arifin H, Raveinal. Kajian penggunaan antibiotik pada pasien sepsis dengan gangguan ginjal. *J Sains Farm Klin*. 2016; 2(2): 129–37.
 23. Jarczak D, Kluge S and Nierhaus A. Sepsis—Pathophysiology and Therapeutic Concepts. *Front. Med*. 2021; 8(6): 1-22
 24. Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: the evolution in definition, pathophysiology, and management. *SAGE Open Med*. 2019; 7: 1-13.
 25. Bush K, Jacoby GA. Updated functional classification of beta lactamases. *Antimicrobial Agents Chemother*. 2010; 54: 969–76
 26. Fadrian. *Antibiotik, infeksi dan resistensi*. Andalas University Press. 2023: 23-30
 27. Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. *Pharmaceuticals Journal*. 2013; 6: 1335–46
 28. Winarto. Prevalensi kuman ESBL (extended spectrum beta lactamase) dari material darah di RSUP dr kariadi tahun 2004-2005. Semarang: Media Medika Indonesia. Fakultas Kedokteran Universitas Diponegoro. 2009: 260–7.
 29. Kuntaman, Mertaniasih NM, Purwanta M. Dalam: bakteri ESBL dari spesimen klinik di RSU dr Soetomo Surabaya. *Simposium penyakit*

infeksi dan problema resistensi antimikroba. Surabaya. FK Unair. 2005:1-9

30. Rupp ME, Fey PD. Extended spectrum β -lactamase (ESBL)-producing enterobacteriaceae considerations for diagnostik, prevention and drug treatment. *Drugs*. 2003; 63 (4): 353-65
31. Goel IN, Sachin S, Kumar CP, Nikhil P, Suneet Y. Different phenotypic methods for detection of ESBL production in bacteria: a review. *J Pharm Sci Innov*. 2014; 3(3): 197-98.
32. Guske CG, Martinez-Martinez L, Canton R, Stefania S, Skov R, Glupczynski Y, *et al*. Guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. *EUCAST*. 2017: 13-25
33. Savira M. Validitas metode konvensional modifikasi terhadap metode konvensional dan chromid tm ESBL untuk deteksi bakteri-bakteri penghasil extended-spectrum beta-lactamases. *JIK*. 2014; 8 (2): 81-90.
34. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum β -lactamase production in enterobacteriaceae: review and bench guide. *Clin Microbiol Infect*. 2008; 14: 90–103
35. Andrews J. Detection of extended-spectrum b-lactamases (ESBLs) in *e. coli* and *klebsiella* species. *BSAC*. 2012:1-2
36. Spanu T, Sanguinetti M, Tumbarello M, D’Inzeo T, Fiori B, Posteraro B *et al*. Evaluation of the new vitek® 2 extended -spectrum beta-lactamase (esbl) test for rapid detection of esbl production in enterobacteriaceae isolates. *J Clin Microbiol*. 2006; 44(9): 3257-326
37. Pana ZD, Zaoutis T. Treatment of extended-spectrum β -lactamase production (ESBLs) infections: what have we learned enterobacteriaceae until now. *F1000Res*. 2018; 1 (2) :1-9
38. Gutierrez G, Ba~no JR. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae in different groups of patients. *Clin Microbil Infect*. 2019; 25 (8): 932-42.
39. Ng TM, Khong WX, Harris PNA, De PP, Chow A, Tambyah PA *et al*. Empiric piperacillin-tazobactam versus carbapenems in the treatment of

- bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae. Plos one. 2016; 11 (4): 1-11
40. Bano JR, Gutierrez BG, Machuca I, Pascual A. Treatment of infections caused by extended spectrum beta lactamase, ampc, and carbapenemase producing enterobacteriaceae..Clin Microbiol Rev. 2018; (2) 14: e00079-17
 41. Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR. Management of infections caused by extended-spectrum β -lactamase- producing enterobacteriaceae: current evidence and future prospects. Expert Review of Anti-Infective Therapy. 2018; 16(3): 205–218.
 42. Zhou S, Wei MQ, Duan M. Role of multidrug resistance associated proteins in drug development. In: Khan AU, Zarrilli R, editor. multidrug resistance: a global concern. Bentaham science: 2012: 3-35.
 43. Sakellariou C, Gürntke S, Steinmetz I, Kohler C, Pfeifer Y, Gastmeier P, *et al.* Sepsis caused by extended-spectrum beta-lactamase (ESBL)- positive k. pneumoniae and e. coli: comparison of severity of sepsis, delay of anti-infective therapy and esbl genotype. PLoS One. 2016; (7): e0158039.
 44. Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram- negative bacterial infections. Expert Rev Anti-Infect Therap. 2017; 15(1): 55–65.
 45. Tamma PD, Aitken SL, Bonom RA, Mathers AJ, Duin DV, Clancy CJ *et al.* Infectious diseases society of america 2022 guidance the treatment of extended-spectrum β -lactamase producing enterobacteriales (ESBL-e), carbapenem-resistant enterobacteriales (CRE), and pseudomonas aeruginosa with difficult-to treat resistance (DTR-P. aeruginosa): AMR Treatment Guidance. Clin Infect Dis. 2022; 75: 187-212
 46. Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M *et al.* High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing enterobacter aerogenes in severely-ill patients. Clin Microbil Infect. 2006; 12(1): 56-62

47. Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how. *Antibiotics*. 2020; 61(9): 1-23
48. Bhat SV, Peleg AY, Lodise TP Jr, Shutt KA, Capitano B, Potoski BA, Paterson DL. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. *Antimicrob Agents Chemother*. 2007 Dec;51(12):4390-5.
49. Johnson SW, Anderson DJ, May DB, Drew RH. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β -lactamase-producing enterobacteriaceae on hospital admission. *Infect Control Hosp Epidemiol*. 2013; 34(4): 385–92
50. Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, *et al*. Clinical risk score for prediction of extended-spectrum beta-lactamase-producing enterobacteriaceae in bloodstream isolates. *Infect. Control Hosp. Epidemiol*. 2017, 38, 266–272.
51. Goodman KE, Lessler J, Cosgrove SE, Harris AD, Lautenbach E, Han JH *et al*. Antibacterial resistance leadership group. a clinical decision tree to predict whether a bacteremic patient is infected with an extended- spectrum β -lactamase-producing organism. *Clin Infect Dis*. 2016 Oct 1;63(7):896-903.
52. Goodman KE, Lessler J, Harris AD, Milstone AM, Tamma PD. A methodological comparison of risk scores versus decision trees for predicting drug-resistant infections: a case study using extended-spectrum beta-lactamase (ESBL) bacteremia. *Infect Control Hosp Epidemiol*. 2019 Apr;40(4):400-407.
53. Ginting JE, Kembaren T. Penilaian akurasi duke score sebagai prediktor infeksi extended-spectrum β -lactamase (ESBL) USU repository. 2015; 1-87
54. Soebroto E. Validasi duke score sebagai prediktor infeksi bakteri family enterobactericeaea penghasil enzim extended beta-lactamase pada pasien di intensive care unit RSUPN dr,cipto mangunkusumo. 2022: 1-59

55. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. *Drug resistance updates*. 2000; 13(5): 303-11
56. Siregar ML, Nelwan EJ, Eppy, Haryanto B, Puspendari N, Sinto R *et al*. Risk factors and mortality outcomes of extended-spectrum beta-lactamase producing *Escherichia coli* bacteremia: a retrospective cohort study from two Indonesian referral hospitals. *F1000Research*. 2022; 11: 1449
57. King DT, Sobhanifar S, Strynadka NCJ. The mechanisms of resistance to β -lactam antibiotics. In: Gotte M, Berghuis A, Matlashewski G, Wainberg M, Sheppard D. *Handbook of antimicrobial resistance*. Springer, New York, NY. 2014.p1-22
58. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis*. 2006;6(10): p629-40
59. FarajzadehSheikh A, Veisi H, Shahin M, Getso M, Farahani A. Frequency of quinolone resistance genes among extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* strains isolated from urinary tract infections. *Trop Med Health*. 2019; 4(47):19.
60. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO *et al*. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Clin Infect Dis*. 2011; 33(8): 1288–94
61. Mody L, Maheshwari S, Galecki A, Kauffman CA, Bradely SF. Indwelling device use and antibiotic resistance in nursing homes: identifying a high-risk group. *J Am Ger Soc*. 2007; 55(12): 1921-6
62. Strausbaugh LJ, Crossley KB, Nurse BA, Thrupp LD. Antimicrobial resistance in long-term-care facilities. *Infect Control Hosp Epidemiol*. 1996; 17(2): 129-40
63. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS *et al*. Utility of the chronic disease score and Charlson comorbidity index as comorbidity measures for use in epidemiologic studies of antibiotic resistant organism. *Am J Epidemiol*. 2005; 161: 483–93

64. Ternavasio-de la Vega HG, Castaño-Romero F, Ragozzino S, Sánchez González R, Vaquero-Herrero MP, Siller-Ruiz M, *et al.* The updated charlson comorbidity index is a useful predictor of mortality in patients with staphylococcus aureus bacteraemia. *Epidemiol Infect.* 2018; 146(16): 2122-2130
65. Soto SM. Importance of biofilms in urinary tract infections: new therapeutic approaches. Hindawi Publishing Corporation *Advances in Biology.* 2014; 7(2014): 1-13
66. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. *J Pathol.* 2007 Jan;211(2):144-56
67. Clifford KM, Dyboarman EA, Haase KK, Maxvill KH, Pass S, Alvarez CA. Challenges with diagnosing and managing sepsis in older adults. *Expert Rev Anti Infect Ther.* 2016;14(2):231-41.
68. Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis. Edisi ke-4.* Jakarta: Sagung Seto. 2021
69. Purba AKR, Mariana N, Aliska G, Wijaya SH, Wulandari RR, Hadi U *et al.* The burden and costs of sepsis and reimbursement of its treatment in a developing country: an observational study on focal infections in indonesia. *International Journal of Infectious Diseases.* 2022; 96: 211–218
70. Qu X, Wang S, Qu Y, Wang H, Ye X, Tang L, Xie Q. Antimicrobial susceptibility characteristics and risk factors associated with adult sepsis in wenzhou, china. *infect drug resist.* 2022; 3(8);15: 915-924.
71. Fataya E, Fadrian, Noer M, Elvira D, Syafrita Y, Suharti N. Characteristics of adult sepsis patients admitted to department of internal medicine, dr. m. djamil general hospital, padang, indonesia. *Bioscientia Medicina: Journal Of Biomedicine & Translational Research;* 2023: 3(7). 3191–8
72. Sakr Y, Elia C, Mascia L, Barberis B, Cardellino S, Livigni S, *et al.* The influence of gender on the epidemiology of and outcome from severe sepsis. *Crit Care.* 2013;17(R50):1-9.
73. Harding AT, Heaton NS. The impact of estrogens and their receptors on immunity and inflammation during infection. *Cancers* 2022; 14: 909.
74. Lakbar I, Einav S, Lalevée N, Martin-Loeches I, Pastene B, Leon M. Interactions between gender and sepsis—implications for the future.

- Microorganisms. 2023; 11: 746.
75. Angstwurm MW, Gaertner R, Schopohl J. Outcome in elderly patients with severe infection is influenced by sex hormones but not gender. *Crit Care Med.* 2005; 33(12):2786-93.
 76. Kweon OJ, Choi JH, Park SK, Park AJ. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. *J Crit Care.* 2014; 29: p965- 70.
 77. Abu-Humaidan AHA, Ahmad FM, Al-Binni MA, Bani Hani A, Abu Abeeleh M. Characteristics of Adult Sepsis Patients in the Intensive Care Units in a Tertiary Hospital in Jordan: An Observational Study. *Crit Care Res Pract.* 2021 Dec 30;2021:2741271.
 78. Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, *et al.* Diagnostic and prognostic value of soluble CD14 subtype (presepsin) for sepsis and community-acquired pneumonia in ICU patients. *Ann Intensive Care.* 2016;6(59):1-11.
 79. Karakike E, Kyriazopoulou E, Tsangaris I, Routsis C, Vincent JL, Giamarellos EJ *et al.* The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. *Crit Care.* 2019;23(387):1-8.
 80. Novita C, Maat S, Tambunan BA. Correlation of procalcitonin level with sepsis degrees based on SOFA score. *Indones J Clin Pathol Med Lab.* 2019;25(3):312-7.
 81. Baig MA, Sheikh S, Hussain E, Bakhtawar S, Khan MS, Mujtaba S, *et al.* Comparison of qSOFA and SOFA score for predicting mortality in severe sepsis and septic shock patients in the emergency department of a low middle income country. *Turk J Emerg Med.* 2018; 18:148-51.
 82. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score: development, utility and challenges of accurate assessment in clinical trials. *Crit Care.* 2019;23(374):1-9.
 83. Fadrian F, Linosefa L, Ridhwan F. M, Hasnah H, Syafa Ayuni A. Multidrug-resistant organisms and determinant factors in sepsis patients.

Iran J Med Microbiol 2023; 17 (5) :10-10

84. Sianipar O, Asmara W, Dwiprahasto I, Mulyono B. Mortality risk of bloodstream infection caused by either *escherichia coli* or *klebsiella pneumoniae* producing extended-spectrum β -lactamase: a prospective cohort study. BMC Res Notes. 2019; 12:179. p1-7
85. Thomas-Rüddel DO, Fröhlich H, Schwarzkopf D, Bloos F, Riessen R. Sepsis and underlying comorbidities in intensive care unit patients analysis of the cause of death by different clinicians—a pilot study. Med Klin Intensivmed Notfmed. 2023 June; p1-6
86. Mirouse A, Vigneron C, Llitjos JF, Chiche JD, Mira JP, Mokart D, *et al.* Sepsis and cancer: an interplay of friends and foes. Am J Respir Crit Care Med. 2020;12; 15;202(12):1625-1635
87. Herbers AHE, de Haan AFJ, van der Velden WJFM, Donnelly JP, Blijlevens NMA. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis 2014; 16: p279–285.
88. Duceau B, Picard M, Pirracchio R, Wanquet A, P`ene F, Merceron S, *et al.* Neutropenic enterocolitis in critically ill patients: spectrum of the disease and risk of invasive fungal disease. Crit Care Med 2019; 47:668– 676.
89. Fentie A, Wondimeneh Y, Balcha A, Amsalu A, Adankie BT. Bacterial profile, antibiotic resistance pattern and associated factors among cancer patients at university of gondar hospital, northwest ethiopia. Infect Drug Resist. 2018; 89110: p2169-2178
90. Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. 2023 Update on sepsis and septic shock in adult patients: management in the emergency department. J Clin Med. 2023 Apr 28;12(9):31
91. Chatterjee S, Bhattacharya M, Todi SK. Epidemiology of adult-population sepsis in india: a single center 5 year experience. Indian J Crit Care Med. 2017 Sep;21(9):573-577.
92. Pitout JDD, Laupland KB. Extended-spectrum β -lactamase-producing

- enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis.* 2008;8(3):159-66.
93. Amelia A, Nugroho A, Harijanto PN. Diagnosis and management of infections caused by enterobacteriaceae producing extended-spectrum beta-lactamase. *Acta Med Indones-Indones J Intern Med.* 2016 ; 48(2).p156-166
94. Siregar C, Wahyuni DD, Yunita R. Prevalence and antimicrobial susceptibility pattern of extended spectrum beta-lactamase (ESBL) producing enterobacteriaceae from blood specimens in rsup h. adam malik medan. *International Journal of Infectious Diseases.*2022; 116.pS7
95. Stone TJ, DeWitt M, Johnson JW, Beardsley JR, Munawar I, Palavecino E, *et al.* Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)- producing *escherichia coli* or *klebsiella pneumoniae*: is esbl-targeted therapy always needed? *Antimicrob Steward Healthc Epidemiol.* 2023; 8(1): e47.
96. Kim M, Song K, Kim C, Choe PG, Park Wb, Bang JH *et al.* Clinical prediction score for community-onset bloodstream infections caused by extendedspectrum beta-lactamase-producing *escherichia coli* and *klebsiella* species. *J Korean Med Sci.* 2019 Apr 15;34(14):e116
97. Hardisman. *Penelitian diagnostik dan prognostik.* Jakarta: Pranedamedia Group.2021
98. Alvarez-Wyssmann V, Reza MV, Martinez-Oliva D, Castañeda P. 1511. Utility of clinical scoring models in predicting community acquired urinary tract infections with extended-spectrum β -lactamase- producing *escherichia coli* in a general hospital in mexico city. *Open Forum Infect Dis.* 2018 ;26: (5): p467–8



